case_images: PMC5941819_01
case_images: An 86-year-old male with bilateral neovascular age-related macular degeneration (AMD) ((a) and (b)). Nine days following bevacizumab injection OD, there was a reduction in intraretinal and subretinal fluid OU ((c) and (d)).
case_images: CRIOPM2018-8561895.001.jpg
case_images: PMC5941819_01_CRIOPM2018-8561895.001.jpg
case_images: fig1
case_images: Visual acuity (VA) was 20/60 OD and 20/150 OS, with decreased central macular thickness in each eye (OU) (Figure 1).
case_images: PMC5941819_02
case_images: An 86-year-old female with neovascular AMD OU ((a) and (b)). Five weeks following aflibercept injection OD, there was a reduction in intraretinal and subretinal fluid OU ((c) and (d)).
case_images: CRIOPM2018-8561895.002.jpg
case_images: PMC5941819_02_CRIOPM2018-8561895.002.jpg
case_images: fig2
case_images: Five weeks later, VA with pinhole was 20/40 OU with decreased central macular thickness OU (Figure 2).
case_images: PMC5941819_03
case_images: A 74-year-old male with bilateral neovascular AMD ((a) and (b)). Six weeks following intravitreal injection of ranibizumab OS, there was a reduction in intraretinal and subretinal fluid OU ((c) and (d)).
case_images: CRIOPM2018-8561895.003.jpg
case_images: PMC5941819_03_CRIOPM2018-8561895.003.jpg
case_images: fig3
case_images: At scheduled followup six weeks later, BCVA was 20/20 OD and 20/50 OS with decreased central macular thickness OU (Figure 3).